<DOC>
	<DOCNO>NCT01039597</DOCNO>
	<brief_summary>A clinical trial conduct test effect potential new treatment patient ulcerative colitis . Study participant give capsule contain either ORE1001 match placebo capsule take medicine mouth six week . Study participant ask visit clinic site ask question ulcerative colitis . Small sample blood drawn study visit monitor participant 's health tiny sample tissue take endoscopy two time determine whether disease get good worse .</brief_summary>
	<brief_title>Safety Activity ORE1001 Subjects With Ulcerative Colitis</brief_title>
	<detailed_description>This Phase Ib/IIa prospective , multicenter , double blind , randomize , placebo control , clinical study evaluate safety , tolerability pilot therapeutic activity ORE1001 , administer capsule mouth , 6 week subject Ulcerative Colitis . Eligible subject randomly assign either ORE1001 placebo , respectively . Sigmoidoscopies biopsy perform first treatment visit week 6 . Subjects instruct self-administer study drug outpatient basis schedule return clinical evaluation week 2 , 4 , 6 Weeks 10-12 .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>1 . Subject documented diagnosis mild moderate Ulcerative Colitis , demonstrate clinically endoscopy Visit 2 . 2 . Baron score great equal 2 baseline . 3 . TrueloveWitt ( modify ) score 14 less . 4 . At least 6 month duration disease 5 . At baseline subject either stable disease stable disease require 5ASA treatment 6 . If 5ASA treatment , subject must stable dose least two week prior screen expect continue dose study complete 7 . Subject normally function major organ system ( aside gastrointestinal tract ) indicate medical history , vital sign , physical exam clinical laboratory ( include hematology , coagulation , chemistry urinalysis ) . 8 . Male female subject 1870 year old 9 . Subject provide voluntary write informed consent participate study . 10 . Subject may childbearing potential , pregnant , nursing , plan pregnancy duration study negative pregnancy test prior enrollment . 11 . Subject agree use medicallyacceptable form contraception screen 30 day final dose study drug . Female partner male subject enrol study also recommend use acceptable method birth control . Males must agree donate sperm entire study 90 day last dose study drug . 1 . A clinically significant medical history , medical find ongoing medical psychiatric condition , opinion Investigator , could jeopardize safety subject , impact validity study result , interfere completion treatment accord protocol . 2 . Subject ALT serum creatinine great 1.5 time upper limit normal range reference lab screening . 3 . Subject , opinion investigator , febrile screening . 4 . Subject use follow treatment IBD : steroid biologic immunomodulators topical treatment ( e.g . enema ) within last 4 week prior baseline , immunosuppressant antimetabolite within precede 6 week , antibiotic use within previous 7 day chronic use antiinflammatory drug ( except aminosalicylates ) within 7 day . 5 . History illicit drug abuse positive urine screen drug abuse history alcohol abuse acknowledge screen visit note subject 's medical record screening . 6 . Subject positive blood screen HIV , Hepatitis B ( HBsAg ) , Hepatitis C. 7 . Subject evidence infectious colitis , e.g. , Clostridium difficile , Amoebiasis , Giardia lamblia stool examination screening . 8 . Subject evidence gastrointestinal parasite per stool ovum parasites test screen . 9 . Subject evidence tuberculosis blood interferon gamma release assay screen . 10 . Any uncontrolled , intercurrent illness ( e.g. , active infection ) . 11 . History gastrointestinal cancer . 12 . Abdominal surgery major surgery within precede 28 day screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>IBD</keyword>
	<keyword>Ulcerative colitis</keyword>
</DOC>